vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Root, Inc. (ROOT). Click either name above to swap in a different company.
Root, Inc. is the larger business by last-quarter revenue ($397.0M vs $247.1M, roughly 1.6× ANI PHARMACEUTICALS INC). On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 21.5%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 24.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Root Insurance Company is an online car insurance company operating in the United States.
ANIP vs ROOT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $397.0M |
| Net Profit | $27.5M | — |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 2.6% |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | 21.5% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $397.0M | ||
| Q3 25 | $227.8M | $387.8M | ||
| Q2 25 | $211.4M | $382.9M | ||
| Q1 25 | $197.1M | $349.4M | ||
| Q4 24 | $190.6M | $326.7M | ||
| Q3 24 | $148.3M | $305.7M | ||
| Q2 24 | $138.0M | $289.2M | ||
| Q1 24 | $137.4M | $254.9M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-5.4M | ||
| Q2 25 | $8.5M | $22.0M | ||
| Q1 25 | $15.7M | $18.4M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $22.8M | ||
| Q2 24 | $-2.3M | $-7.8M | ||
| Q1 24 | $18.2M | $-6.2M |
| Q4 25 | 14.1% | 2.6% | ||
| Q3 25 | 15.9% | 0.1% | ||
| Q2 25 | 6.6% | 7.1% | ||
| Q1 25 | 13.3% | 6.8% | ||
| Q4 24 | -2.3% | 10.7% | ||
| Q3 24 | -13.8% | 11.3% | ||
| Q2 24 | 3.7% | 1.3% | ||
| Q1 24 | 14.8% | 2.1% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -1.4% | ||
| Q2 25 | 4.0% | 5.7% | ||
| Q1 25 | 8.0% | 5.3% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 7.5% | ||
| Q2 24 | -1.7% | -2.7% | ||
| Q1 24 | 13.2% | -2.4% |
| Q4 25 | $1.14 | $0.35 | ||
| Q3 25 | $1.13 | $-0.35 | ||
| Q2 25 | $0.36 | $1.29 | ||
| Q1 25 | $0.69 | $1.07 | ||
| Q4 24 | $-0.45 | $1.42 | ||
| Q3 24 | $-1.27 | $1.35 | ||
| Q2 24 | $-0.14 | $-0.52 | ||
| Q1 24 | $0.82 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $669.3M |
| Total DebtLower is stronger | — | $200.3M |
| Stockholders' EquityBook value | $540.7M | $284.3M |
| Total Assets | $1.4B | $1.7B |
| Debt / EquityLower = less leverage | — | 0.70× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $669.3M | ||
| Q3 25 | $262.6M | $653.3M | ||
| Q2 25 | $217.8M | $641.4M | ||
| Q1 25 | $149.8M | $609.4M | ||
| Q4 24 | $144.9M | $599.3M | ||
| Q3 24 | $145.0M | $674.8M | ||
| Q2 24 | $240.1M | $667.2M | ||
| Q1 24 | $228.6M | $640.5M |
| Q4 25 | — | $200.3M | ||
| Q3 25 | — | $200.4M | ||
| Q2 25 | — | $200.1M | ||
| Q1 25 | — | $200.0M | ||
| Q4 24 | — | $200.1M | ||
| Q3 24 | — | $300.9M | ||
| Q2 24 | — | $300.1M | ||
| Q1 24 | — | $299.3M |
| Q4 25 | $540.7M | $284.3M | ||
| Q3 25 | $505.8M | $265.0M | ||
| Q2 25 | $436.8M | $244.5M | ||
| Q1 25 | $418.6M | $228.7M | ||
| Q4 24 | $403.7M | $203.7M | ||
| Q3 24 | $405.9M | $181.9M | ||
| Q2 24 | $455.8M | $151.3M | ||
| Q1 24 | $452.0M | $165.7M |
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.6B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.4B |
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.98× | ||
| Q3 24 | — | 1.65× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | — | 1.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $206.5M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $206.5M | ||
| Q3 25 | $44.1M | $57.6M | ||
| Q2 25 | $75.8M | $52.0M | ||
| Q1 25 | $35.0M | $26.8M | ||
| Q4 24 | $15.9M | $195.7M | ||
| Q3 24 | $12.5M | $49.4M | ||
| Q2 24 | $17.4M | $62.6M | ||
| Q1 24 | $18.3M | $14.5M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | $195.3M | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | $62.4M | ||
| Q1 24 | $13.7M | $14.3M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | 59.8% | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | 21.6% | ||
| Q1 24 | 10.0% | 5.6% |
| Q4 25 | 0.5% | 0.0% | ||
| Q3 25 | 2.7% | 0.0% | ||
| Q2 25 | 1.9% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 1.3% | 0.1% | ||
| Q3 24 | 3.2% | 0.0% | ||
| Q2 24 | 3.2% | 0.1% | ||
| Q1 24 | 3.3% | 0.1% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 2.36× | ||
| Q1 25 | 2.23× | 1.46× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ROOT
Segment breakdown not available.
